mezagitamab   Click here for help

GtoPdb Ligand ID: 10609

Synonyms: TAK-079 | TAK079
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mezagitamab (TAK-079) is a humanized, IgG1, cell-depleting anti-CD38 monoclonal antibody [3-4]. Anti-CD38 therapeutics were primarily developed as treatments for multiple myeloma [5], but have subsequently been discovered to offer potential in solid tumours and autoimmune diseases [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
TAK‐079 depletes CD38 cells by inducing antibody‐dependent cell‐mediated cytotoxicity and complement‐dependent cytotoxicity [3]. Although extensive pharmacokinetic and pharmacodynamic data for TAK-079 has been published [3], we have been unable to locate a binding affinity value for the antibody-target interaction. TAK-079 is likely to be one of the antibodies claimed in Takeda patent WO2012092612A1 (potentially that referred to as Ab79 therein), and we have included the binding affinity for the Ab79 construct in the interactions table [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD38 Hs Antibody Binding 8.3 pKd - 1
⤷ pKd 8.3 (Kd 5.5x10-9 M) [1]
Description: Binding affinity of Ab79 for CD38 ectodomain, determined by Biacore SPR analysis.